Tirzepatide has firmly established itself as one of the most powerful and fastest-acting medications for both type 2 diabetes management and chronic weight reduction by early 2026. Sold under the brand name Mounjaro for diabetes and Zepbound for obesity in most markets, this once-weekly injectable is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) […]